WO2001028567A3 - Aminoalkylenephosphonates for treatment of bone disorders - Google Patents

Aminoalkylenephosphonates for treatment of bone disorders Download PDF

Info

Publication number
WO2001028567A3
WO2001028567A3 PCT/US2000/028713 US0028713W WO0128567A3 WO 2001028567 A3 WO2001028567 A3 WO 2001028567A3 US 0028713 W US0028713 W US 0028713W WO 0128567 A3 WO0128567 A3 WO 0128567A3
Authority
WO
WIPO (PCT)
Prior art keywords
aminoalkylenephosphonates
alk
treatment
bone disorders
po3h2
Prior art date
Application number
PCT/US2000/028713
Other languages
French (fr)
Other versions
WO2001028567A2 (en
Inventor
R Keith Frank
Original Assignee
Dow Chemical Co
R Keith Frank
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co, R Keith Frank filed Critical Dow Chemical Co
Priority to CA002382877A priority Critical patent/CA2382877A1/en
Priority to JP2001531397A priority patent/JP2003512331A/en
Priority to US10/088,884 priority patent/US6794371B1/en
Priority to EP00972234A priority patent/EP1225903A2/en
Priority to AU10926/01A priority patent/AU1092601A/en
Publication of WO2001028567A2 publication Critical patent/WO2001028567A2/en
Publication of WO2001028567A3 publication Critical patent/WO2001028567A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for preventing or minimizing loss of bone mineral in mammals which method comprises administering to a mammal an amount of an aminoalkylenephosphonate which is effective to prevent or minimize loss of bone mineral density. The aminoalkylenephosphonates of the present invention should have at least one R-N(Alk-PO3H2)2 group or at least two RR´N-Alk-PO3H2 groups wherein R and R´ can be, same or different, aliphatic or cyclic moiety, and Alk is an alkylene group having from 1 to 4 carbon atoms.
PCT/US2000/028713 1999-10-18 2000-10-17 Aminoalkylenephosphonates for treatment of bone disorders WO2001028567A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002382877A CA2382877A1 (en) 1999-10-18 2000-10-17 Aminoalkylenephosphonates for treatment of bone disorders
JP2001531397A JP2003512331A (en) 1999-10-18 2000-10-17 Aminoalkylene phosphonate for treatment of bone disorders
US10/088,884 US6794371B1 (en) 1999-10-18 2000-10-17 Aminoalkylenephosphonates for treatment of bone disorders
EP00972234A EP1225903A2 (en) 1999-10-18 2000-10-17 Aminoalkylenephosphonates for treatment of bone disorders
AU10926/01A AU1092601A (en) 1999-10-18 2000-10-17 Aminoalkylenephosphonates for treatment of bone disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16001999P 1999-10-18 1999-10-18
US60/160,019 1999-10-18

Publications (2)

Publication Number Publication Date
WO2001028567A2 WO2001028567A2 (en) 2001-04-26
WO2001028567A3 true WO2001028567A3 (en) 2001-11-29

Family

ID=22575141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/028713 WO2001028567A2 (en) 1999-10-18 2000-10-17 Aminoalkylenephosphonates for treatment of bone disorders

Country Status (6)

Country Link
EP (1) EP1225903A2 (en)
JP (1) JP2003512331A (en)
CN (1) CN1378454A (en)
AU (1) AU1092601A (en)
CA (1) CA2382877A1 (en)
WO (1) WO2001028567A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2721040A1 (en) * 2011-06-17 2014-04-23 Centre National De La Recherche Scientifique Bifunctional phosphonate chelating agents
RU2527439C2 (en) * 2011-10-24 2014-08-27 Открытое акционерное общество "Полипласт" (ОАО "Полипласт") Biocidal additive for concretes and mortars

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411941A2 (en) * 1989-08-04 1991-02-06 The Dow Chemical Company Process for purifying aminomethylenephosphonic acids
WO1994000145A1 (en) * 1992-06-30 1994-01-06 The Dow Chemical Company Targeted delivery of growth factors for bone regeneration
US5385893A (en) * 1993-05-06 1995-01-31 The Dow Chemical Company Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
US5714604A (en) * 1993-05-06 1998-02-03 The Dow Chemical Company Process for the preparation of azamacrocyclic or acyclic aminophosphonate ester derivatives
US5902825A (en) * 1997-01-07 1999-05-11 Mitreoak, Ltd. Composition and method for the palliation of pain associated with diseases of the bone and bone joints

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411941A2 (en) * 1989-08-04 1991-02-06 The Dow Chemical Company Process for purifying aminomethylenephosphonic acids
WO1994000145A1 (en) * 1992-06-30 1994-01-06 The Dow Chemical Company Targeted delivery of growth factors for bone regeneration
US5385893A (en) * 1993-05-06 1995-01-31 The Dow Chemical Company Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
US5714604A (en) * 1993-05-06 1998-02-03 The Dow Chemical Company Process for the preparation of azamacrocyclic or acyclic aminophosphonate ester derivatives
US5902825A (en) * 1997-01-07 1999-05-11 Mitreoak, Ltd. Composition and method for the palliation of pain associated with diseases of the bone and bone joints

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; WANG, WENJIA ET AL: "Effect of TATMP [N,N',N'',N'''-tetrakis(phosphonomethyl)-1,4,7,10- tetraazacyclododecane] on the growth kinetics of calcite crystals", XP002174221, retrieved from STN Database accession no. 113:14960 *
JEE W S S ET AL: "EFFECTS OF N N N' N' ETHYLENEDIAMINETETRAMETHYLENE PHOSPHONIC ACID ON CORTICAL BONE REMODELING IN THE ADULT DOG", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 92, no. 3, 1988, pages 335 - 342, XP001014791, ISSN: 0041-008X *
MILLER S C ET AL: "EFFECTS OF N N N' N' ETHYLENEDIAMINETETRAMETHYLENE PHOSPHONIC-ACID AND 1 HYDROXYETHYLIDENE-1 1-BISPHOSPHONIC-ACID ON CALCIUM ABSORPTION PLASMA CALCIUM LONGITUDINAL BONE GROWTH AND BONE HISTOLOGY IN THE GROWING RAT", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 77, no. 2, 1985, pages 230 - 239, XP001014788, ISSN: 0041-008X *
MOORE N C ET AL: "Effects of intraperitoneal administration of hexasodium N,N,N',N'-ethylenediaminetetramethylenephosphonate on rat bone metabolism.", FUNDAMENTAL AND APPLIED TOXICOLOGY, (1990 APR) 14 (3) 491-501., XP001014568 *
SHUICHULI JISHU (1989), 15(6), 370-3 *

Also Published As

Publication number Publication date
EP1225903A2 (en) 2002-07-31
CN1378454A (en) 2002-11-06
JP2003512331A (en) 2003-04-02
AU1092601A (en) 2001-04-30
WO2001028567A2 (en) 2001-04-26
CA2382877A1 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
TJ392B (en) Fraction of copolymer-1 and method prodaction of it, composition for the treatment of multiple sclerosis, farmaceutical composition, method for the t reatment of multiple sclerosis.
DE69628559D1 (en) Carbonyl-piperaznyl und piperidinyl derivate zur hemmung farnesyl protein transferase
EP0283675A3 (en) Dental plaque and dental caries inhibiting agent and compositions containing such an agent
EP0401747A3 (en) Use of rapamycin and derivatives and prodrugs thereof in the manufacture of a medicament for inhibiting transplant rejection in mammals
AU3142597A (en) Dha-pharmaceutical agent conjugates
CA2296036A1 (en) Dolastatin 15 derivatives
ZA955206B (en) Certain arylsulfonamido-substituted hydroxamic acids
AU2711295A (en) Combination treatment for inhibiting bone loss
HK1041481A1 (en) Protein kinase inhibitors for treatment of neurological disorders
FR2762843B1 (en) NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BG101714A (en) Improvements in the function of the endometrium or in functions related to it
EP0658348A3 (en) Aqueous solution inclusion complexes of benzothiophene compounds with cyclodextrins.
HK1043809A1 (en) Pharmaceutical composition for treating papillomavirus tumours and infection.
AU2634597A (en) Compounds with growth hormone releasing properties
EP0973518A4 (en) Semi-synthetic studies toward didemnin analogues
WO2001028567A3 (en) Aminoalkylenephosphonates for treatment of bone disorders
WO2000029012A8 (en) Methods of alleviating cancer symptoms
CA2042934A1 (en) Treatment of ocular hypertension with an ocular synergistic combination
CA2183247A1 (en) Antimalarial Korupensamines and Pharmaceutical Compositions and Medical Uses Thereof
MY122052A (en) Method of treating tourette''s syndrome
AU3043697A (en) Anticoagulant peptidyl-arginine aldehyde derivatives
EP1107789A4 (en) Compositions and methods for protecting organs, tissue and cells from immune system-mediated damage
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
GR3033968T3 (en) Inhibition of trauma-induced tumor growth.
ZA912236B (en) Hydroxymethyl-indolizidines and quinolizidines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10088884

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000972234

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2382877

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 008141231

Country of ref document: CN

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 531397

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10926/01

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000972234

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000972234

Country of ref document: EP